

Patient Self-Management in PAP Therapy

The possibilities of mobile apps and the effects on treatment success





Patient Self-Management in PAPTherapy

The possibilities of mobile apps and the effects on treatment success

Prevalence of Sleep-Disordered Breathing (SDB)

Sleep-Disordered Breathing (SDB) is a widespread chronic illness associated with increased mortality and an enormous economic burden for society. (Bally S., 2016), (Arnaud C., 2009) Study results indicate that about four percent of adult men and two percent of adult women are affected by SDB. Based solely on an AHI \geq 5, the estimated prevalence is substantially higher at 24 percent of men and nine percent of women. (Young et al., 1993 and 2003).

ŤŤŤŤŤŤŤŤŤŤ *************

The latest epidemiological studies, however, estimate the prevalence of SDB significantly higher than previously assumed, at 49 percent of men and 23 percent of women. (Yetkin O., Kunter E., Gunen H., 2008), (Epidemiology, 2017), (Heinzer R. et al., 2015)




Figure 1: Effects of Sleep-Disordered Breathing

The greatest challenge: Patient acceptance and adherence

PAP therapy is a demonstrably effective treatment for Sleep-Disordered Breathing. Diverse studies have proven the effectiveness of CPAP therapy, depending on the degree of compliance or with compliance of more than four hours per night. (Palm, Midgren, Theorell-Haglöw, Janson, & Lindberg, 2017), (Antic et al., 2011), (Billings M.E. et al., 2014), (Bouloukaki I. et al., 2017), (Kasai T., Narui K. et al., 2008), (Kingshott R.N. et al., 2000), (Peker Y. et al., 2016), (Abuzaid A.S. et al., 2017), (Weaver et al., 2007)



- Longer usage times of more than six hours per night are associated with significantly improved symptoms, better cognitive function and notably reduced blood pressure. (Weaver T.E., 2007), (Barbé F., 2010)
- The therapy, however, is not without side effects. Consequently, even patients with severe cases of Obstructive Sleep Apnea Syndrome (OSAS) show suboptimal acceptance of and adherence to therapy. (Engleman H.M., Wild M.R., 2003), (Weaver T.E., Mancini C., Maislin G., 2012), (McEvoy R.D., Antic N.A., Heeley E., 2016)
- Approximately 46 to 83 percent of OSAS patients use their devices regularly for more than four hours per night. (Engleman H.M., Wild M.R., 2003), (Weaver T.E. et al., 2008), (Orth M. et al., 2006)




Figure 2: Increasing proportion of non-compliant patients over time. Engleman H.M., Wild M.R., 2003

• Furthermore, even with good CPAP adherence of more than four hours nightly and a low AHI, up to 40 percent of OSAS patients still suffer from daytime sleepiness, which, in turn, can have a negative effect on therapy adherence. (Antic, 2011)

Multiple factors affect therapy adherence

Comorbidities: Critical factors are subjective perceptions of daytime symptoms (sleepiness as measured by Epworth Sleepiness Scale) combined with the severity of SDB. (Engleman H.M., 1996), (Orth et al., 2006) Others include the existence of depression (Borel J.C. et al., 2013), a high BMI (Marques S. et al., 2017) or other comorbidities such as hypertension and diabetes. (Nakamura H. et al., 2016), (Marques S. et al., 2017).

Technological progress: Significant improvement in CPAP compliance has been reported (Rotenberg B.W., Murariu D., Pang K.P., 2016) and attributed to technological progress in the development of devices (more comfort functions) and masks (better wearing comfort).






Figure 3: Factors and barriers to therapy adherence from the patient's surroundings (Kanfer F.H., 2006) (Berger et al., 2007)

Long-term adherence supported by early intervention

Low therapy adherence after one month is generally a good predictor of low adherence at 12 months (Chai-Coetzer C.L. et al., 2014). Therefore, it is very important to provide comprehensive patient care in the first weeks after therapy begins. Long-term compliance can be achieved when such intense care includes giving patients information about their disorder and devices, encouraging them to develop skill and competence, and supporting them with problem-solving during the initial days and weeks. Providing this type of patient care in cases of chronic diseases like SDB, however, is possible to a limited extent. Therapy adherence can be improved only with enormous investments in time, work and resources. For example, repeated intense conversations in which patients are told about the benefits of PAP usage generally increase the patient's satisfaction with information flow and level of care and positively affect therapy adherence. (Hoy C.J., 1999), (Lewis K.E., 2004).

Providing comprehensive care in times of a pandemic is that much more challenging because sleep therapy patients can have only limited or no personal contact with their caregivers. That situation underscores the need for additional communication channels and smoothes the way for appsupported treatment strategies with prisma APP.

prisma APP – the Löwenstein app for a good night



Patients who become actively engaged in their therapy and regularly receive information and support as needed exhibit significantly higher therapy compliance. An always available mobile application like prisma APP from Löwenstein Medical is a low-cost alternative to personal contact. The app can positively affect motivation by regularly showing the patient his therapy progress and engaging him in treatment. (Isetta V. et al., 2017). (Fox N. et al., 2012), (Shaugnessy G.F. et al., 2019), (Marques S. et al., 2017), (Engleman H.M., 2018).

The preliminary results of a controlled randomized study with the prisma APP show much higher adherence in the group that voluntarily used the



prisma APP as a supplement to treatment (332 min +/-159 min) than the control group with standard therapy (219 min +/-190 min), (Franke et al., 2020).*

The prisma APP is not a replacement for the interaction between expert and patient, but it can be additional support. If patients are to use their devices long-term, they need continuous guidance and information to keep them motivated throughout the therapy period. Patients have shown ready acceptance of app-supported treatment, which works reliably and contributes to sustained improvement of sleep quality.




Figure 4: CPAP adherence within 12 weeks of follow-up, preliminary analysis n= 38 patients

prisma APP for patients:

Communication as information guide and aid to self-help

Patients generally rely on apps for positive reinforcement of therapy success in which their behavior plays a critical role and confirmation of the proper functioning of the device. In the self-management approach, persons affected by sleep apnea are activated and trained to practice sleep-promoting behavior. The supporting pillars of app-based communication with the prisma APP are:

- Brief daily summaries of therapy results and goal achievement
- Detailed weekly reports on relevant therapy parameters
- Setting reasonable, measurable and authentic goals
- Automated, sensible interim goals with regular progress checks and results monitoring
- Patient's personal observation of symptoms and physiological processes based on data and analyses with recommendations for action
- Regular, personalized feedback on therapy success and goal attainment sent to patient (Kuna S.T. et al., 2011), (Hibbard J.H., 2004), (Berger A., 2007)
- Option to exchange data with the doctor or caregiver (for example, before a visit to doctor or a telephone call)
- Recommendation to contact the doctor on the basis of data (e.g., persistent elevated AHI, or many side effects or other therapy problems).



In addition to the information about therapy, such as mean pressure level, mask air-tightness, AHI and therapy use, other parameters like estimated deep sleep time are transmitted for the overall evaluation of sleep quality.*

If a problem arises, the patient's responses to four fundamental questions in the standard therapy check could lead to an automatic recommendation for an intervention or to the suggestion that the patient contact an expert. The point of the intervention is to build up patient knowledge and competence so he can help himself in the first instance. The app serves as a contemporary supplement to the traditional instructions for use on paper with:

- Brief usage videos on handling humidifiers, devices and masks
- Tips on mask corrections
- Hygiene recommendations
- Therapy tips on comfort parameters
- Additional recommendations on making contact and arranging appointments with experts

For the experts: focus on essentials and look toward future potential

Experts are not replaced by Web-based communication with prisma APP; they are freed up to use their time more effectively. Patients' frequently asked questions are automatically filtered by prisma APP and answered with short explanatory videos or offers.

Then interventions by experts could be initiated early for patients who cannot be successfully treated independently or who have particularly serious problems. These patient groups are encouraged to contact experts. According to lsetta et al., distance learning (teleconsultation and telephone contact) has already proven to be an effective way to transfer knowledge as an alternative to a face-to-face meeting. (lsetta et al., 2014). An intervention based on data and reports from the patient could even go so far as to refer the patient to the sleep lab again.

The app is responsible for processing large amounts of data, identifying patients with serious problems and intervening at an early stage. Depending on the seriousness of the reported problem, prisma APP and prisma CLOUD prioritize patients for a targeted intervention.

By means of Web and app-based communication channels between experts and patients such as prisma APP and prisma CLOUD, experts and service providers – depending on the healthcare system – are given the infrastructure to convey to patients new information about therapy and appropriate accessories.

^{*} see White Paper: "Sleep Quality under CPAP/APAP Therapy links compliance, leakage, AHI and therapeutic success" at www.loewensteinmedical.com







Figure 5: Support of therapy adherence in a Web-based application



Summary

The focus is on a cost-effective, barrier-free system for everyday patient use in which relevant parameters (e.g., deep sleep indicator*) are compiled in a comprehensive evaluation of sleep quality.

App-based communication with prisma APP cannot replace the trusting expert-patient relationship. However, it can serve as a low-cost, resource-conserving alternative that helps the patient to help himself, builds confidence in therapy, increases motivation long term, and eliminates side effects and problems by means of early intervention. prisma APP offers the patient complete and secure access to relevant therapy data and functions as a guide and resource for all related support questions. With game-like challenges, the prisma APP can give the patient holistic support and the lighten the expert's workload.



* see White Paper: "Sleep Quality under CPAP/APAP Therapy links compliance, leakage, AHI and therapeutic success" at www.loewensteinmedical.com



Referenzen

Arnaud C., Dematteis M., Pepin J.L., Baguet J.P., Levy P.: Obstructive sleep apnea, immuno-inflammation and atherosclerosis. Semin. Immunopathol. 2009; 31: 113–125.

Bailly S., Destors M., Grillet Y., Richard P., Stach B., Vivodtzev I., Timsit J.F., Lévy P., Tamisier R., Pépin J.L.: Obstructive sleep apnea: a cluster analysis at time of diagnosis. PLoS One 2016; 11: e0157318.

Barbé F., Duran-Cantolla J., Capote F. et al.: Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 718–726.

Berger A. et al.: Multidisciplinary perspectives on attention and the development of self-regulation, in: Progress in Neurobiology 82 (2007), 256-286

Berger T., (2016): Internet-based treatments - experiences from Sweden. An interview with Gerhard Andersson. Verhaltenstherapie 23:211-214

Borel J.C., Tamisier R., Dias-Domingos S. et al.: Type of mask may impact on continuous positive airway pressure adherence in apneic patients. PLoS One 2013; 8: e64382.

Chai-Coetzer C.L., Luo Y.M., Antic N.A. et al.: Predictors of long-term adherence to continuous positive airway pressure therapy in patients with obstructive sleep apnea and cardiovascular disease in the SAVE study. Sleep 2013; 36: 1929–1937.

Deutsche Gesellschaft für Schlafforschung und Schlafmedizin. S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Somnologie 2017. 21:2-44. DOI 10.1007/s11818-016-0097-x. Online publiziert: 27.02.2017.

DiMatteo M.R.: Variations in patients' adherence to medical recommendations:a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209.

Engleman H.M., Asgari-Jirhandeh N., McLeod A.L., Ramsay C.F., Deary I.J., Douglas N.L. (1996): Self-reported use of CPAP and benefits of CPAP Therapy. A patient survey. Chest 109: 1470-1476.

Engleman H.M., Wild M.R.: Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Med. Rev. 2003; 7: 81–99.

Engleman H.M., Stitt C., Creswick L. et al.: Effects on CPAP use of a patient support mobile app. Eur Respir J 2018; 52: Suppl. 62, PA2257

Epidemiology, risk factors and phenotypes of sleep breathing disorders; Presse Med. 2017 Apr; 46(4): 388-394. doi: 10.1016/j.lpm.2016.11.002.

Franke C., Schaefer R., Grimm A., Gruenewald A., Schwaibold M., Brandenburg U., Alshut R.: Impact of smart digital feedback, motivation and assistance on CPAP adherence: a randomized controlled trial; Posterpublikation der Zwischenergebnisse, ERS 2020

Fox N., Hirsch-Allen A.J., Goodfellow E., Wenner J., Fleetham J., Ryan C.F. et al.: The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: a randomized controlled trial. Sleep 2012;35(4):477e81

Gottlieb D.J., Yenokyan G., Newman A.B., O'Connor G.T., Punjabi N.M., Quan S.F., Redline S. et al.: Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study, Circulation 2010; 122: 352-360.

Heffner J.E., Yelena Rozenfeld Y., Kai M., Stephens E.A., Brown L.K.: Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. Chest 2012, 141:1414–1421.

Heinzer R., Vat S., Marques-Vidal P., Marti-Soler H., Andries D., Tobback N., Mooser V., Preisig M., Malhotra A., Waeber G. et al., Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir. Med. 2015; 3: 310–8.

Hibbard J.H., Stockard J., Mahoney E.R. et al.: Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers Health Serv Res, 39 (2004),

Hoy C.J., Vennelle M., Kingshott R.N., Engleman H.M., Douglas N.J.: Can intensive support improve continuous positive airway pressure use in patients with the sleep apnea/hypopnea syndrome? Am J Respir Crit Card Med. 1999;159(4 pt 1): 1096-1100

Isetta V., Leon C., Torres M. et al.: Telemedicine-based approach for obstructive sleep apnea management: building evidence. Interact J Med Res 2014; 3: e6.

Isetta V., Torres M., González K., Concepción Ruiz, Dalmases M., Embid C., Navajas D., Farré R., Montserrat J.M., A New mHealth application to support treatment of sleep apnoea patients, Journal of Telemedicine and Telecare 2017, Vol. 23(1) 14–18

Kanfer F.H., Reinecker H., Schmelzer D., Selbstmanagement-Therapie, Ein Lehrbuch für die klinische Praxis. Springer-Verlag Berlin Heidelberg. 2006, 554, eBook ISBN 978-3-642-19366-8.

Kribbs N.B., Pack A.I., Kline L.R. et al.: Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 147: 1162–1168.

Kuna S.T., Gurubhagavatula I., Maislin G. et al.: Noninferiority of functional outcome in ambulatory management of obstructive sleep apnea. Am J Respir Crit Care Med 2011; 183: 1238–1244.

Lewis K.E., Seale L., Bartle I.E., Watkins A.J., Ebden P.: "Early predictors of CPAP use for the treatment of obstructive sleep apnea" Sleep 2004; 27: 134-138.

Lorenzi-Filho G., Fernanda R., Almeida A., Strollo P.J.: "Treating OSA: Current and emerging therapies beyond CPAP", Respirology (2017) 22, 1500–1507,doi: 10.1111/resp.13144.



Marin J.M., Carrizo S.J., Vicente E., Agusti A.G.: Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365:1046–1053.

Marques S.: The impact of a telemedicine monitoring on positive airway pressure in naïve obstructive sleep apnea patients' outcomes: A randomized controlled trial, Sleep Medicine 2017 40 Supplement I (e83)

McEvoy R.D., Antic N.A., Heeley E. et al.: CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919-931.

Nakamura H., Tohyama K., Takara C., Kouki T., Okada T., Tamaki Y., Yamakawa I.: Predictors of long-term use of continuous positive airway pressure in patients with obstructive sleep apnea in a single institution in Okinawa; Sleep 2016 39 SUPPL. 1 (A155)

Orth M., Duchna H.W., Kotterba S., Schultze-Werninghaus G., Rasche K.: Long-term compliance of CPAP therapy in obstructive sleep apnea syndrome

Palm A., Theorell-Haglow J., Ljunggren M., Janson C., Lindberg E.,: Factors influencing adherence to continuous positive airway pressure treatment in obstructive sleep apnea and mortality associated with treatment failure – a national registry-based cohort study, Sleep Medicine 2018 51 (85 - 91)

Peker Y., Hedner J., Norum J., Kraiczi H., Carlson J.: "Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up" Am J Respir Crit Care Med 2002; 166: 159-165.

Punjabi N.M., Caffo B.S., Goodwin J.L., Gottlieb D.J., Newman A.B., O'Connor G.T., Rapoport D.M. et al.: "Sleep-disordered breathing and mortality: a prospective cohort study" PLoS Med 2009; 6: e1000132.

Ronald J., Delaive K., Roos L., Manfreda J., Bahammam A., Kryger M.H.: Health care utilization in the 10 years prior to diagnosis in obstructive sleep apnea syndrome patients. Sleep 1999, 22:225–229.

Rotenberg B.W., Murariu D., Pang K.P.: Trends in CPAP adherence over twenty years of data collection: a flattened curve. J. Otolaryngol. Head Neck Surg. 2016; 45: 43.

Sateia M.J.: Neuropsychological impairment and quality of life in obstructive sleep apnea. Clin Chest Med 2003, 24:249–259.

Sawyer A.M., Gooneratne N.S., Marcus C.L., Ofer D., Richards K.C., Weaver T.E.: A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. Sleep Med Rev 2011;15(6):343e56.

Schaeffer D., Hämel K. 2017. Sammelwerksbeitrag Kooperative Versorgungsmodelle. Eine international vergleichende Betrachtung In: Handbuch Gesundheitssoziologie. Jungbauer-Gans M., Kriwy P. (Eds); Wiesbaden: Springer VS: 1-18.

Toy E.L., Beaulieu N.U., Mchale J.M. et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441.

Umefjord, Petersson, & Hamberg, 2003: Reasons for Consulting a Doctor on the Internet: Web Survey of Users of an Ask the Doctor Service, Journal of Medical Internet Research 5(4):e26 · November 2003, DOI: 10.2196/jmir.5.4.e26 · Source: PubMed

Yaggi H.K., Concato J., Kernan W.N., Lichtman J.H., Brass L.M., Mohsenin V.: "Obstructive sleep apnea as a risk factor for stroke and death" N Engl J Med 2005; 353: 2034-2041,

Yetkin O., Kunter E., Gunen H.: CPAP compliance in patients with obstructive sleep apnea syndrome, Sleep Breath 2008; 12: 365-367.

Weaver T.E., Grunstein R.R.: "Adherence to continuous positive airway pressure therapy: the challenge to effective treatment" Proc Am Thorac Soc 2008; 5:173-178.

Weaver T.E., Maislin G., Dinges D.F. et al.: Relationship between hours of CPAP use and achieving normal levels of sleepiness and daytime functioning. Sleep 2007; 30: 711–719.

Weaver T.E., Mancini C., Maislin G. et al.: Continuous positive airway pressure treatment of sleepy patients with milder obstructive sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized clinical trial. Am J Respir Crit Card Med. 2012;186(7):677-683.

World Health Organization: "Adherence to long-term therapies: evidence for action." WHO Library, 2003





Löwenstein Medical Technology Kronsaalsweg 40 22525 Hamburg, Germany T: +49 40 54702-0 F: +49 40 54702-461 info@loewensteinmedical.de Löwenstein Medical Arzbacher Straße 80 56130 Bad Ems, Germany T. +49 2603 9600-0 F. +49 2603 9600-50 info@loewensteinmedical.com



